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Richard A. Rovin, MD3
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Purpose	Reasons for the well-described disparity in outcomes between African American (AA) and nonHispanic white (NHW) women with invasive breast cancer are unclear, making it difficult to identify
solutions. This study examined the effects of demographics, biomarkers, tumor characteristics,
cancer stage, morphology, and treatment variables on overall and cancer-free survival in these
patient populations.
Methods	We retrospectively reviewed data for 6231 patients diagnosed with invasive breast cancer throughout
an integrated health system from January 2006 through March 2015. Included for analysis were
5023 NHW and 413 AA women. All category and continuous variables in the study were described
in the two groups using appropriate statistics. Kaplan-Meier method of survival with log-rank test
was used to compare the two racial groups (NHW and AA). Cox proportional hazards regression
was used to find hazard ratios for the predictors of survival and recurrence-free survival probability.
Propensity probability match method (1:1) was used to match 319 NSW women to 319 similar AA
women. Matching was done using all significant predictors, including demographic variables.
Results 	
Compared to NHW women, AA women presented with invasive breast cancer at a younger age
(P<0.001) and had a higher proportion of stage IV cancers (P<0.001), which were more often infiltrating
ductal carcinoma (P<0.003) and poorly differentiated (P<0.001). Within 10-year follow-up, AA women
had shorter overall and recurrence-free survival (log-rank P<0.001), were 1.4 times more likely to die
(P=0.009), and were twice as likely to have recurrence (P<0.001) than NHW women. In the matched
groups, overall survival was similar for AA and NHW (log-rank P=0.0793); however, recurrence-free
survival was higher in NHW than in AA women (P=0.047).
Conclusions	When presenting characteristics of AA and NHW women with invasive breast cancer are matched,
disparity in overall mortality and rate of recurrence appears to be reduced or perhaps eliminated,
suggesting invasive breast cancers in AA and NHW women respond similarly to treatment. Further
study is needed to explore the true effect of biological factors; however, rectifying delivery of and
access to care might be expected to mitigate, in large part, the racial disparity currently seen in breast
cancer outcomes. (J Patient Cent Res Rev. 2018;5:218-228.)
Keywords	invasive breast cancer; racial disparity; overall survival; recurrence; oncology; propensity match

A

frican American (AA) women tend to be
diagnosed with breast cancer at an earlier age
and with less favorable tumor characteristics,
leading to worse outcomes in terms of overall survival
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and recurrence-free survival (RFS) when compared
with non-Hispanic white (NHW) women.1-3 According
to the National Cancer Institute (NCI), cancer health
disparities are defined as “adverse differences in cancer
incidence (new cases), cancer prevalence (all existing
cases), cancer death (mortality), cancer survivorship,
and burden of cancer or related health conditions that
exist among specific population groups in the United
States.”1 These specific population groups are often
characterized by race and ethnicity.
Original Research

Complex and interrelated factors contribute to
the observed disparities in cancer incidence and
death among racial and ethnic groups, including
socioeconomic status.4,5 According to NCI statistics
from 2000 to 2004, the incidence of breast cancer
among AA women was 118.3 per 100,000 whereas the
incidence rate for NHW women was 132.5. Despite
this, the death rate for AA women was 33.8 per 100,000
compared to 25.0 for NHW women.6
Although AA women have a lower incidence of breast
cancer, their cancers are associated with a higher rate of
mortality and recurrence compared to NHW women.7-9
Many of the reasons for racial differences in mortality
and cancer recurrence are not completely understood.
Lower socioeconomic status was associated with an
increase in mortality in a meta-analysis that included
20 studies, and the authors concluded that further
exploration of associations between ethnicity and
variation in primary tumor biology was needed.4
Additional proposed differences include cancer stage
at presentation, differences in care, differences in
treatment, and differences in (unfavorable) tumor
biology.9-12 For example, triple-negative breast cancers
are more common in AA women than in NHW
women, and these cancers are associated with higher
recurrence and decreased survival.13,14 Meta-analysis
of 145 studies demonstrated a 22% increase in overall
mortality risk in AA women,15 which increased to
27% in a follow-up meta-analysis of 20 studies from
1980 to 2005.4 When human epidermal growth factor
receptor 2 (HER2)-positive cancers were combined
with both estrogen receptor (ER)- and progesterone
receptor (PR)-positive and -negative tumors, AA
women demonstrated a 32% increased risk for
mortality. Interestingly, when socioeconomic status
was used as an adjusting factor, there were no racial
differences in women presenting with stage I cancers
of any subtype or in those presenting with stage II–IV
ER/PR/HER2 subtypes, although the contribution of
socioeconomic status to ethnic disparity varied widely
within tumor subtype.5
In this study, we review the outcomes for AA
and NHW women diagnosed with invasive breast
cancer from January 2006 through March 2015
at a large integrated health care system based in
Wisconsin. Demographics, biomarker expression,
tumor characteristics, screening methods, treatment
Original Research

modalities, overall survival, and RFS for AA and
NHW women were compared to determine the extent
of racial disparity within the study cohort.
The amount and quality of data collected was rich
enough to allow the creation of matched cohorts to test
if any disparity remained when factors other than race
were the same. We therefore created a matched cohort
containing equal numbers of NHW and AA women,
using the propensity-match technique, and compared
survival and recurrence metrics, hypothesizing
that when matched for demographic, molecular,
histological, and treatment characteristics, overall
survival and RFS would be similar between AA and
NHW women. While demonstrating similarity in
outcomes of matched patients would not determine
clinical treatment decisions in individuals who
present with breast cancer, it could steer researchers
toward ascertaining the true causes of the differences
in outcomes seen between AA and NHW women,
possibly access to and engagement with health care
services.

METHODS

Study Population
The cancer registry maintained by Aurora Health Care,
an integrated health system and largest health care
provider in Wisconsin, was accessed after institutional
review board approval of this retrospective study. The
medical records and cancer registry data for patients
diagnosed with invasive breast cancer from January
2006 to March 2015 were reviewed. Only AA and
NHW women diagnosed with invasive breast cancer
were included in this study.
Clinical Data
For each woman diagnosed with invasive breast
cancer, typical demographic data as well as cancer
stage, grade, differentiation, tumor size, receptor (ER,
PR, HER2) status, and treatments such as surgery,
chemotherapy, hormonal therapy, immunotherapy, and
radiation were recorded. Both breast cancer recurrence
and all-cause mortality were included in the data.
Statistical Analysis
All categorical variables were described as count and
percentage. Wherever appropriate, the chi-squared test
and/or Fisher’s exact test were used to compare the AA
and NHW groups. Continuous variables were described
www.aurora.org/jpcrr
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as mean, median, and standard deviation. The KaplanMeier method was used to compare time-to-event data,
including all-cause mortality and cancer recurrence
over the 10-year follow-up. Study participants were
considered to be at risk from the date of diagnosis
of invasive breast cancer to the date of termination
of follow-up (March 31, 2015), date of breast cancer
recurrence (cancer-free survival analysis), or date of
death, whichever occurred first.
Propensity score matching was performed based
on demographic, prognostic, and treatment factors:
race; age; screening mammography; biopsy; tumor
morphology, differentiation, and size; expression of
estrogen, progesterone, and HER2; chemotherapy;
hormonal therapy; and immunotherapy. Variables for
matching were identified by using univariate analysis for
the demographics, biomarkers, tumor characteristics,
and treatment variables. Using logistic regression, a
predictive probability for whether a woman was likely
to be AA or NHW was computed. Matching was done
using an iterative process by matching probability
for an AA woman to the same probability of a NHW
woman. The predictive probabilities were matched
up to 0.0001 precision using 1:1 (nearest-neighbor)
matching. In this method, both groups (AA and NHW)
are first sorted by the predicted probability. Then, the
first AA woman is selected to find its closest match
based on propensity score from NHW women. This
procedure was repeated for all women. The mean
difference logit score was 0.0185, with standard error
of 0.0169.
According to post-hoc power calculation, an overall
sample size of 638 subjects (of which 319 are in one
group and 319 in the other group) achieved 92% power
at a 0.05 significance level when the hazard ratio (HR)
is actually 1.0. The equivalence ratio was 2.0. It was
anticipated that the proportion of subjects in which
the event (death, recurrence) was observed during the
study would be 0.15 in each of the two groups. These
calculations assumed that the HR remained constant
throughout the study period and that Cox proportional
hazards regression or the equivalence log-rank test was
used to analyze the data.
All statistical tests were two-sided and used an alpha
of 0.05. Analyses were conducted using SAS® 9.4
software (SAS Institute Inc., Cary, NC).
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RESULTS

Patient Demographic, Biomarker Expression,
and Treatment
Data was retrospectively collected for 6231 women
with a primary diagnosis of invasive breast cancer.
For the purpose of this study, we excluded 795 women
who were identified as Asian, American Indian, Asian
Indian or Pakistani, Chinese, Filipino, Japanese,
Korean, “other,” or “unknown” race, or who were
denoted as Hispanic (4.3%). The remaining cohort
of 5436 included 5023 NHW (92.4%) and 413 AA
(7.6%) women (Table 1). During the follow-up period,
696 women (12.8%) died and 779 women (14.3%) had
cancer recurrence.
Age: The median age of presentation was 52.4 years
for AA women and 60 years for NHW women. The
proportion of women 20 to 59 years old at diagnosis
was significantly higher for AA than for NHW women
(P<0.001).
Survival and Recurrence: Mean survival time was
shorter for AA women compared to NHW women (3
years vs 3.7 years, P<0.001). Both the rate of mortality
(17.0% vs 12.5%, P=0.009) and cancer recurrence
(23.8% vs 13.6%, P<0.001) were higher among AA
women, while the probability of overall survival and
RFS was lower (log-rank P<0.001). The difference in
percentage in overall survival for the two groups at the
end of 2, 4, 6, 8, and 10 years was 0.0, 4.45, 9.99, 9.57,
and 4.42, and the difference in RFS was 0.0, 8.75, 12.7,
17.3, and 17.1, respectively.
Pathology, Grade, and Stage: The incidence of ductal
carcinoma was higher among AA women, whereas
lobular and other carcinomas were higher among NHW
women (P<0.001). AA women also had more poorly
differentiated tumors (P<0.001) and presented with
more advanced (II, III, or IV) cancer stages (P<0.001).
However, mean tumor size was similar across both
groups (45.9 cm vs 53.2 cm, P=0.351).
Molecular Markers: The proportion of women who
presented with ER-expressing (P<0.001) or PRexpressing (P<0.001) tumors was lower among AA
women, whereas the proportion of women with HER2expressing tumors (P=0.667) was similar among
AA and NHW women. Among the remaining tumor
subtypes, there were more NHW women with luminal
Original Research

Table 1. Comparison of Patient Demographic, Biomarker, Treatment Characteristics Between Black and White
Women Diagnosed With Invasive Breast Cancer
Characteristic

Overall (N=5436)

NHW (n=5023)

AA (n=413)

Age, n (%)
20–39 years
40–59 years
60–79 years
≥ 80 years

271 (5.0)
2318 (42.6)
2215 (40.8)
632 (11.6)

230 (4.6)
2106 (41.9)
2076 (41.3)
611 (12.2)

41 (9.9)
212 (51.3)
139 (33.7)
21 (5.1)

Mammography, n (%)
Yes
No
Biopsy, n (%)
Yes
No
Morphology (carcinoma), n (%)
Duct and lobular
Duct only
Lobular only
Other

<0.0001

<0.0001
2832 (52.1)
2604 (47.9)

2661 (53.0)
2362 (47.0)

171 (41.4)
242 (58.6)
0.0133

4952 (91.1)
484 (8.9)

4562 (90.8)
461 (9.2)

390 (94.4)
23 (5.6)

188 (3.5)
4226 (77.7)
555 (10.2)
467 (8.6)

174 (3.5)
3877 (77.2)
532 (10.6)
440 (8.8)

14 (3.4)
349 (84.5)
23 (5.6)
27 (6.5)

0.0026

Grade differentiation,* n (%)

<0.0001

Well

1252 (23.7)

1185 (24.3)

67 (16.5)

Moderate

2365 (44.8)

2222 (45.6)

143 (35.3)

Poor

1663 (31.5)

1468 (30.1)

195 (48.2)

Cancer stage,* n (%)
I
II
III
IV

2538 (48.2)
1798 (34.2)
662 (12.6)
263 (5.0)

2389 (49.1)
1656 (34.0)
585 (12.0)
235 (4.8)

149 (37.6)
142 (35.9)
77 (19.4)
28 (7.1)

Estrogen receptor,* n (%)
Positive
Negative

4288 (79.8)
1085 (20.2)

4037 (81.3)
927 (18.7)

251 (61.4)
158 (38.6)

Progesterone receptor,* n (%)
Positive
Negative

3806 (71.0)
1554 (29.0)

3,601 (72.7)
1,353 (27.3)

205 (50.5)
201 (49.5)

<0.0001

<0.0001

<0.0001

HER2,* n (%)

0.6670

Positive

680 (13.5)

631 (13.6)

49 (12.8)

Negative

4351 (86.5)

4017 (86.4)

334 (87.2)

247 (5.1)
3169 (65.2)
369 (7.6)
324 (6.7)
752 (15.5)

227 (5.0)
2997 (66.6)
339 (7.5)
313 (6.7)
627 (13.9)

20 (5.6)
172 (48.0)
30 (8.4)
11 (3.1)
125 (34.9)

Cancer category,* n (%)
HER2
Luminal A
Luminal B
Triple-positive
Triple-negative
Surgery, n (%)
Partial
Total
None

Original Research

P

<0.0001

0.2427
3406 (62.6)
689 (12.7)
1341 (24.7)

3158 (62.9)
626 (12.5)
1239 (24.7)

248 (60.1)
63 (15.2)
102 (24.7)
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Table 1 (continued). Comparison of Patient Demographic, Biomarker, Treatment Characteristics Between Black and
White Women Diagnosed With Invasive Breast Cancer
Characteristic

Overall (N=5436)

NHW (n=5023)

AA (n=413)

P

Radiation,* n (%)
Yes
No

3126 (58.1)
2259 (41.9)

2911 (58.4)
2077 (41.6)

215 (54.2)
182 (45.8)

Chemotherapy,* n (%)
Yes
No

2641 (48.6)
2793 (51.4)

2389 (47.6)
2632 (52.4)

252 (61.0)
161 (39.0)

Hormonal therapy,* n (%)
Yes
No

3758 (69.1)
1677 (30.9)

3554 (70.8)
1468 (29.2)

204 (49.4)
209 (50.6)

Immunotherapy,* n (%)
Yes
No

116 (2.0)
5319 (98.0)

109 (2.2)
4913 (97.8)

7 (1.7)
406 (98.3)

Mortality, n (%)
Dead
Alive

696 (12.8)
4740 (87.2)

626 (12.5)
4397 (87.5)

70 (16.9)
343 (83.1)

Cancer recurrence,* n (%)
Yes
No

779 (14.4)
4645 (85.6)

681 (13.6)
4331 (86.4)

98 (23.8)
314 (76.2)

Tumor size,* n (mean ± SD)

5419
(46.4 ± 152.7)

5008
(45.9 ± 152.2)

411
(53.2 ± 158.9)

0.3510

Survival month,* n (mean ± SD)

5436
(43.4 ± 29.6)

5023
(44.0 ± 29.7)

413
(36.1 ± 27.3)

<0.0001

0.1023

<0.0001

<0.0001

0.5204

0.0087

<0.0001

AA, African American; HER2, hormone epidermal growth factor receptor 2; NHW, non-Hispanic white; SD, standard deviation.
*Indicates some values were missing for these characteristics.

A tumors and there were more AA women with triplenegative breast tumors (P<0.001).
Treatment: The proportion of women who received
surgery of any type (P=0.243), radiation (P=0.102), and
immunotherapy (P=0.520) was similar for both groups
of women. More NHW women received hormonal
therapy (P<0.001), and AA women were more likely
to receive chemotherapy (P<0.001).
Screening: Fewer AA women received mammograms
(41.4% vs 53%, P<0.001), whereas fewer NHW women
underwent a tumor biopsy (90.8% vs 94.4%, P=0.013).
Multivariate Analysis
Multivariate analysis of overall survival and RFS showed
that race (when adjusted for all other demographics,
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biomarker expression, tumor characteristics, and
treatment modalities) was a significant predictor of
mortality and cancer recurrence (Tables S1 and S2,
online only). AA women had a 1.7 times higher risk of
dying (P=0.0004) and a 1.4 times higher risk of cancer
recurrence (P=0.0103) within 10 years.
Separate multivariate analyses were conducted for AA
and NHW cohorts for all-cause mortality and cancer
recurrence. Significant factors (adjusting for all other
factors) for all-cause mortality in AA were presentation
with later stages (III or IV vs I) of cancer (HR: 3.5,
95% confidence interval [CI]: 1.4–9.2, P=0.01 for
stage III; HR: 15.3, 95% CI: 4.3–54.3, P<0.01 for
stage IV) and whether the woman underwent surgery
(partial vs none) (HR: 0.4, 95% CI: 0.2–0.9, P=0.031).
In NHW women several factors were found to be

Original Research

significant: 1) whether the woman had been screened
by mammography, 2) the grade of the tumor at
presentation, 3) the stage of the cancer, 4) the size
of the tumor, 5) HER2 expression, 6) whether she
underwent surgery, 7) whether she was treated with
chemotherapy, 8) whether she received hormonal
therapy, and 9) whether she received radiation therapy.

odds of dying and recurrence were 1.4 and 2.0 times
higher, respectively, for AA women compared to NHW
women. Among ER-, PR-, and HER2-positive cases,
AA women had an increased risk of recurrence of
approximately twofold. These findings are consistent
with other similar population studies reported in the
literature.16,17

For cancer recurrence our analyses resulted in similar
findings. Significant factors for AA women were 1)
whether the woman received a screening mammogram,
2) the stage of the cancer at presentation, 3) whether
surgery had been performed, and 4) whether she
had received radiation therapy. In NHW women
significant predictors for tumor recurrence were 1)
age, 2) mammographic screening, 3) grade of tumor
at presentation, 4) stage of the cancer, 5) tumor size,
6) expression of either PR or HER2, 7) whether the
women underwent surgery, and 8) treatment with
chemotherapy, hormonal therapy, or radiation therapy.

Using multivariate logistic regression, we identified
significant predictors of mortality and recurrence and
found differences between AA and NHW women. For
AA women, cancer stage and surgery were significant
predictors for overall survival, whereas age, tumor
characteristics, HER2 expression, and treatment were
significant predictors of overall survival for NHW
women. Among AA women, screening, cancer stage,
surgery, and radiation were significant predictors for
cancer recurrence, whereas in NHW women, age,
tumor characteristics, HER2 and PR expression, and
treatment were significant. Although our dataset did
not have socioeconomic status indicators, Newman et
al showed that lower socioeconomic status resulted in
increased mortality.4 We would expect a similar effect
within our patient cohort. Additionally, we assumed
that the treatment plan for each patient was based on
the limited set of biomarkers available.

Propensity-Matched Cohort
Propensity matching on the variables noted in Table 2
resulted in a 1:1 matched cohort of 319 AA and 319
NHW women. Table 2 also confirms the precision of the
matching algorithm, as all the significant differences
in the unmatched cohort became nonsignificant in the
matched cohort. For the matched cohort (Table 3),
overall survival was slightly better for NHW women
but did not reach statistical significance (P=0.0793).
RFS, however, was slightly longer for NHW women
compared to AA women (P=0.0466). Figure 1 shows
Kaplan-Meier curves for overall survival and RFS for
unmatched and matched cohorts.

DISCUSSION

After reviewing outcomes of AA and NHW women
with invasive breast cancer treated within a large
health system, our findings were consistent with others
published in the literature: 1) AA women had a higher
mortality rate and rate of recurrence compared to
their NHW counterparts; and 2) AA women presented
with breast tumors carrying worse prognostic factors
compared to NHW women. These prognostic factors
included advanced stage at presentation with tumors
that were more often poorly differentiated, less likely to
express estrogen or progesterone positivity, and more
likely to be triple-negative in makeup. As a result, the

Original Research

In the propensity-matched cohorts, we controlled for
patient characteristics, treatment regimens, and tumor
characteristics. The only primary outcome measures
that were significantly different on this analysis were
mean length of survival and time to recurrence —
both shorter in AA women. Because we looked at allcause mortality and not cancer-specific mortality, the
approximately 8-month difference in mean survival
may be attributable to noncancer deaths related to
poorer baseline health and more medical comorbidities
in AA women.2 One of the limitations of propensity
matching is that the sample size is reduced to the size
of the smaller group. However, propensity matching
does control variables and thus increases the sensitivity
for the comparison.
It is important to understand the reason(s) underlying
the race-related disparity in outcomes in women with
breast cancer so that useful solutions can be identified.
True biological differences are addressed differently
than access to care.
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Table 2. Total and Propensity-Matched Cohorts, Divided by Race, for Women Diagnosed With Invasive Breast Cancer
Unmatched cohorts
NHW
(N=5023)

AA
(N=413)

20–39 years

230 (4.6)

40–59 years
60–79 years

Characteristic

AA
(N=319)

41 (9.9)

26 (8.2)

25 (7.8)

2106 (41.9)

212 (51.3)

150 (47.0)

165 (51.7)

2076 (41.3)

139 (33.7)

112 (35.1)

112 (35.1)

611 (12.2)

21 (5.1)

31 (9.7)

17 (5.3)

Age (years), n (%)

≥80 years

Propensity-matched cohorts
NHW
(N=319)

P

P

<0.0001

Mammography, n (%)

0.1857

<0.0001

0.8737

Yes

2661 (53.0)

171 (41.4)

145 (45.5)

147 (46.1)

No

2362 (47.0)

242 (58.6)

174 (54.5)

172 (53.9)

Biopsy, n (%)

0.0133

0.8244

Yes

4562 (90.8)

390 (94.4)

308 (96.5)

309 (96.9)

No

461 (9.2)

23 (5.6)

11 (3.5)

10 (3.1)

Morphology (carcinoma), n (%)
Duct and lobular

0.0026

0.7248

174 (3.5)

14 (3.4)

10 (3.1)

8 (2.5)

Duct only

3877 (77.2)

349 (84.5)

269 (84.3)

279 (87.5)

Lobular only

532 (10.6)

23 (5.6)

22 (6.9)

17 (5.3)

Other

440 (8.8)

27 (6.5)

18 (5.6)

15 (4.7)

Grade differentiation,* n (%)

<0.0001

0.7699

Well

1185 (24.3)

67 (16.5)

55 (17.2)

Moderate

2222 (45.6)

143 (35.3)

107 (33.5)

114 (35.7)

Poor

1468 (30.1)

195 (48.2)

157 (49.2)

148 (46.4)

I

2389 (49.1)

149 (37.6)

125 (39.2)

137 (43.0)

II

1656 (34.0)

142 (35.9)

127 (39.8)

121 (37.9)

III

585 (12.0)

77 (19.4)

60 (18.8)

54 (16.9)

IV

235 (4.8)

28 (7.1)

7 (2.2)

7 (2.2)

Positive

4037 (81.3)

251 (61.4)

195 (61.1)

200 (62.7)

Negative

927 (18.7)

158 (38.6)

124 (38.9)

119 (37.3)

Positive

3601 (72.7)

205 (50.5)

171 (53.6)

179 (56.1)

Negative

1353 (27.3)

201 (49.5)

148 (46.4)

140 (43.9)

Yes

2389 (47.6)

252 (61.0)

173 (54.2)

188 (58.9)

No

2632 (52.4)

161 (39.0)

146 (45.8)

131 (41.1)

Cancer stage,* n (%)

57 (17.9)

<0.0001

Estrogen receptor,* n (%)

0.7987

<0.0001

Progesterone receptor,* n (%)

0.6835

<0.0001

Chemotherapy,* n (%)

0.5245

<0.0001

Hormonal therapy,* n (%)

0.2308

<0.0001

0.4277

Yes

3554 (70.8)

204 (49.4)

164 (51.4)

174 (54.6)

No

1468 (29.2)

209 (50.6)

155 (48.6)

145 (45.4)

AA, African American; NHW, non-Hispanic white.
*Indicates total numbers of patients are not equal to 5023 for NHW and 413 for AA for characteristic due to missing data.
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Table 3. Summary of Primary Outcome Measures for Unmatched and Matched Cohorts on Univariate Regression
Unmatched cohort
NHW
(N=5023)

AA
(N=413)

Dead

626 (12.5)

Alive

Matched cohort
NHW
(N=319)

AA
(N=319)

70 (19.9)

33 (10.3)

41 (12.9)

4397 (87.5)

343 (83.1)

286 (89.7)

278 (87.2)

Yes

681 (13.6)

98 (23.8)

44 (13.8)

55 (17.2)

No

4331 (86.4)

314 (76.2)

275 (86.2)

264 (82.8)

3.41 (4.0)

2.5 (3.50)

<0.0001

3.58 (4.08)

2.58 (3.42)

0.0041

Death, HR (95% CI)

ref

1.74
(1.33–2.29)

<0.0001

ref

1.46
(0.98–2.32)

0.1186

Recurrence, HR (95% CI)

ref

1.99
(1.56–2.56)

<0.0001

ref

1.31
(0.86–2.0)

0.2087

Death, OR (95% CI)

ref

1.43
(1.10–1.88)

0.0089

ref

1.30
(0.79–2.08)

0.3235

Recurrence, OR (95% CI)

ref

1.98
(1.56–2.53)

<0.0001

ref

1.30
(0.85–2.0)

0.2299

Characteristic
Mortality, n (%)

0.0087

Cancer recurrence, n (%)

Time to event (death, recurrence)
in years, median (IQR)

P

P
0.3226

<0.0001

0.2291

Survival, log-rank K-M

16.54

<0.0001

3.80

0.0793

Recurrence, log-rank K-M

48.01

<0.0001

3.96

0.0466

AA, African American; CI, confidence interval; HR, hazard ratio; IQR, interquartile range; K-M, Kaplan-Meier;
NHW, non-Hispanic white; OR, odds ratio; ref, reference.

Differences in tumor biology do exist, cannot be
overlooked, and do present an opportunity for
precision medicine intervention. For example, it has
been reported that the tumor microenvironment in AA
women demonstrates increased levels of resistin and
interleukin-6, and that AA women have higher levels
of proinflammatory tumor-associated macrophages and
higher microvessel density.18 In our retrospective study,
differences in tumor biology were not included in the
database and thus were not analyzed between races. Our
study did control for treatment, however, and showed that
when AA and NHW women with similar characteristics
received similar treatment, their outcomes also were
similar. This suggests that the difference in outcomes in
the unmatched cohort is due to differences in the receiving
of treatment rather than in the effect of treatment.
Differences in health care equivalency have been
documented. Annual age-adjusted breast cancer
mortality rates in the United States, Chicago, and

Original Research

New York City from 1980 to 2005 show that the
mortality for each cohort was similar until 1991,
when the curves started to diverge; NHW women
demonstrated decreasing mortality while mortality
among AA women increased.19 The authors concluded
that the disparity in mortality related to disparity in
access to care in three specific domains: the ability to
access mammography, the quality of mammography
available, and access to quality treatment.19 This data
has informed sweeping changes in health care policy
in Chicago; the Illinois Reducing Breast Cancer
Disparities Act created the Breast Cancer Quality
Consortium to improve the quality of mammography
and helped expand the Illinois Breast and Cervical
Cancer Program to provide screening, diagnosis,
and treatment for all uninsured women in Illinois.20
These health care policy decisions were effective —
mortality for AA women in Chicago suffering from
breast cancer decreased from 40.9% (1999–2005) to
35.2% (2006–2013).21
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Figure 1. Overall and disease-free survival in African American (AA) women compared to non-Hispanic white

(NHW) women. A: Overall 10-year survival for women diagnosed with invasive breast cancer for AA and NHW
women. B: Overall 10-year survival for women diagnosed with invasive breast cancer for matched cohort of AA and
NHW women. C: Disease-free 10-year survival for women diagnosed with invasive breast cancer for AA and NHW
women. D: Disease-free 10-year survival for women diagnosed with invasive breast cancer for matched cohort of
AA and NHW women.

Limitations
As noted throughout this report, there are limitations
to our study methods and findings. The retrospective
nature of data collection did not allow differences in
tumor biology or socioeconomic variables between
races to be analyzed. Though propensity score
matching controls for variables to provide strong
sensitivity in comparisons, a disadvantage of this
statistical method is that sample size is reduced to
the size of the smaller subpopulation. Not all patient
biomarkers, which typically guide clinical treatment,
226 JPCRR • Volume 5, Issue 3 • Summer 2018

were noted in the database. However, all available
variables were analyzed as covariates. Among
analyzed variables, a small number of values were
missing from the dataset.

CONCLUSIONS

When presenting characteristics of AA and NHW
women with invasive breast cancer are matched,
disparity in overall mortality and rate of recurrence
appears to be reduced or perhaps eliminated. NWH
women did show an advantage in recurrence-free
Original Research

survival. Our novel use of propensity score matching
confirms that when matched for biomarkers, tumor
characteristics, and treatment, AA and NHW women
with breast cancer had mostly similar outcomes.
Therefore, differential outcomes are more likely
due to differences in screening (which in turn affect
distribution of age, stage, and grade of tumor at
presentation), differences in baseline health, and
differences in access to treatment (which can be
societal, institutional, or cultural). Potential solutions
to glaring racial disparities in breast cancer outcomes
should look toward improving access to and delivery
of care. Better RFS among NHW women might be
due to factors — treatment adherence, socioeconomic
status, or other unknown factors — beyond the scope
of this study. Further study is needed to explore the
effect of these factors.

Patient-Friendly Recap
• Due to oft-reported differences in outcome, race
is viewed as a significant factor in treatment of
invasive breast cancer.
• Authors compared two breast cancer cohorts
(African American, non-Hispanic white)
in which each patient was matched to a
racial counterpart in terms of demographic,
biomarker, tumor, cancer stage, and treatment
characteristics.
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